Our gMCS computational framework is applied to evaluate the lethality of ribonucleotide reductase catalytic subunit M1 (RRM1) in multiple myeloma (MM), a hematological cancer that remains for the most part an incurable disease. Here, RRM1 is linked to Miyoshi myopathy.